T89 capsule

DRUG4 trials

Sponsors

Tasly Pharmaceuticals, Inc.

Conditions

Acute Mountain Sickness (AMS)Chronic Stable Angina PectorisCovid19

Phase 2

Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

CompletedNCT03552263

Tasly Pharmaceuticals, Inc.Acute Mountain Sickness (AMS)

Start: 2018-06-07End: 2019-11-10Updated: 2019-11-13

Phase 3

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

RecruitingNCT03789552

Tasly Pharmaceuticals, Inc.Chronic Stable Angina Pectoris

Start: 2019-08-01End: 2027-03-31Target: 765Updated: 2025-04-09

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

CompletedNCT04993729

Tasly Pharmaceuticals, Inc.Acute Mountain Sickness (AMS)

Start: 2021-07-21End: 2023-05-26Updated: 2024-08-13

Unknown Phase

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Tasly Pharmaceuticals, Inc.Covid19

Updated: 2023-08-08

Related Papers

Pleiotropic Effects of Icariside II on the Cardiovascular System: Novel Applications of Ethnopharmacology in Targeting Vascular Remodeling

Journal of Cardiovascular Pharmacology2022-07-01